For instance, the multiple sclerosis oral treatment dimethyl fumarate acting via up-regulation of the nuclear factor-erythroid-2-related factor 2 (Nrf2)-dependent antioxidant response was tested in vitro, showing positive results against oxaliplatin-, cisplatin-, and bortezomib- (but not paclitaxel-) induced inhibition of neurite outgrowth [58]. This evidence concerns the gene NFE2L2 and multiple sclerosis.